^
Association details:
| Biomarker: | LDH elevation + BRAF mutation |
|---|---|
| Cancer: | Melanoma |
| Drug Class: | PD1 inhibitor + CTLA4 inhibitor |
| Direction: | Resistant |
Evidence:
Source:
Title:
Efficacy of checkpoint inhibition in advanced acral melanoma
Published date:
05/19/2021
Excerpt:
Twenty-four AM patients received at least one dose of anti-PD1 plus anti-CTLA4...AM patients treated with first-line combination therapy had a median PFS of 3.8 months (95% CI 2.8-NR) and median OS of 7.63 months (95% CI 6.12-NR)….Elevated LDH levels and the presence of BRAF mutation were significantly associated with lower OS.
DOI:
10.1200/JCO.2021.39.15_suppl.e21527
